BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0022
-0.0001 (-4.35%)
Mar 28, 2025, 5:37 PM CET
-90.00%
Market Cap 1.21M
Revenue (ttm) 2.87M
Net Income (ttm) -7.44M
Shares Out 549.69M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,438,953
Average Volume 8,114,738
Open 0.0024
Previous Close 0.0023
Day's Range 0.0022 - 0.0027
52-Week Range 0.0021 - 0.0360
Beta -2.86
RSI 34.35
Earnings Date Apr 25, 2025

About BioSenic

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult ti... [Read more]

Industry Biotechnology
Sector Healthcare
CEO François Rieger
Country Belgium
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2023, BioSenic's revenue was 543,000, an increase of 104.14% compared to the previous year's 266,000. Losses were -28.78 million, 843.9% more than in 2022.

Financial Statements

News

There is no news available yet.